-
-
-
-
-
-
-
GRI Bio, Inc (GRI) Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Re
-
-
-
-
-
-
-
GRI Bio, Inc (GRI) regains compliance with Nasdaq rule
-
-
-
-
-
-
-
Ascendiant Capital Starts GRI Bio, Inc. (GRI) at Buy
-
-
-
-
-
-
-
GRI Bio, Inc (GRI) Announces 1:13 Reverse Share Split
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

